Subcutaneous Herceptin Meets Goals In Phase III Trial

New subcutaneous formulation of Roche's breast cancer biologic Herceptin is comparable to intravenous version, prompting the companies to file for approval in Europe in 2012. Yet, U.S. filing could take longer.